(Q37733561)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Ceftaroline for complicated skin and skin-structure infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

3

G Ralph Corey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

Martin E Stryjewski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

1197-1206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Clinical practice. Infection associated with prosthetic joints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003777026

10.1517/14656561003777026

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20402556%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference